CalciMedica (CALC) CFO receives 67,728 stock options at $0.585 strike price

Rhea-AI Filing Summary

CalciMedica, Inc. Chief Financial Officer Stephen Bardin received a grant of employee stock options covering 67,728 shares of common stock at an exercise price of $0.585 per share. Beginning April 1, 2026, 1/48th of the option shares vest in equal monthly installments over four years, with vesting starting only after the company files a Form S-8 for shares added under its 2023 Equity Incentive Plan.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Bardin Stephen

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (Right to Buy)	67,728	$0.00	--

Holdings After Transaction: Employee Stock Option (Right to Buy) — 67,728 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 67,728 options Exercise price: $0.585 per share Post-transaction derivative holdings: 67,728 options +2 more

5 metrics

Option grant size 67,728 options Employee stock option grant to CFO Stephen Bardin

Exercise price $0.585 per share Strike price for newly granted options

Post-transaction derivative holdings 67,728 options Total options held after grant in this award

Vesting start date April 1, 2026 1/48th of options vest monthly from this date, subject to S-8 filing

Expiration date April 4, 2036 Option expiration for this grant

Key Terms

Employee Stock Option, Form S-8, 2023 Equity Incentive Plan, evergreen provision, +1 more

5 terms

Employee Stock Option financial

"security_title": "Employee Stock Option (Right to Buy)""

An employee stock option is a promise that lets a worker buy company shares later at a predetermined price, often after they stay for a certain period or meet performance goals — think of it like a coupon that locks in today's price for a future purchase. It matters to investors because options align employees’ incentives with company performance, can increase the number of shares outstanding (dilution) when exercised, and represent a compensation cost that affects reported profits and shareholder value.

Form S-8 regulatory

"no shares shall vest until the filing of the Company's registration statement on Form S-8"

A Form S-8 is a U.S. Securities and Exchange Commission registration that lets a public company set aside shares for employee benefit plans and stock-based compensation. Think of it as opening a dedicated account that authorizes the company to issue or reserve stock for workers and directors; it matters to investors because it enables share dilution when those awards are granted or exercised and signals how management is compensated and incentivized.

2023 Equity Incentive Plan financial

"under the Company's 2023 Equity Incentive Plan on January 1, 2026"

evergreen provision financial

"shares authorized for issuance under the Company's 2023 Equity Incentive Plan ... pursuant to an annual "evergreen" provision"

An evergreen provision is a clause in a financing or contract that automatically renews or replenishes the arrangement unless one party actively cancels it, like a subscription that keeps renewing each term. For investors it matters because it creates predictable, ongoing access to funding or ongoing contractual obligations — helping liquidity and planning — but can also hide long-term commitments or dilution risks if not reviewed.

grant, award, or other acquisition financial

"transaction_code_description": "Grant, award, or other acquisition""

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bardin Stephen

(Last) (First) (Middle)

C/O CALCIMEDICA, INC.

505 COAST S. BLVD, #307

(Street)

LA JOLLA CALIFORNIA 92037

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CalciMedica, Inc. [ CALC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$0.585	04/05/2025		A		67,728		(1)	04/04/2036	Common Stock	67,728	$0	67,728	D

Explanation of Responses:

1. Beginning April 1, 2026, 1/48th of the shares subject to the option vest in equal monthly installments over a four year period, provided, however, that no shares shall vest until the filing of the Company's registration statement on Form S-8 covering the shares of Common Stock that were automatically added to the shares authorized for issuance under the Company's 2023 Equity Incentive Plan on January 1, 2026 pursuant to an annual "evergreen" provision.

	/s/ John Dunn, Attorney-in-Fact	04/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did CalciMedica (CALC) report for Stephen Bardin?

CalciMedica reported that CFO Stephen Bardin received an employee stock option grant for 67,728 shares of common stock at a $0.585 exercise price. This is a compensation-related award, not an open-market share purchase or sale.

What is the exercise price of Stephen Bardin’s new CalciMedica (CALC) stock options?

The employee stock options granted to CFO Stephen Bardin have an exercise price of $0.585 per share. This means he can buy CalciMedica common stock at $0.585 once the options vest and are exercised.

How do Stephen Bardin’s CalciMedica (CALC) options vest?

Beginning April 1, 2026, 1/48th of Stephen Bardin’s options vest in equal monthly installments over four years. However, no shares vest until CalciMedica files a Form S-8 covering additional shares under its 2023 Equity Incentive Plan.

When do Stephen Bardin’s CalciMedica (CALC) stock options expire?

Stephen Bardin’s employee stock options expire on April 4, 2036. He may exercise vested options at $0.585 per share any time before this expiration date, subject to the plan’s terms and company policies.

Did Stephen Bardin buy or sell CalciMedica (CALC) shares in the market?

No market purchase or sale occurred in this filing. The transaction is a grant of 67,728 employee stock options as compensation, classified as an acquisition of derivative securities rather than an open-market trade.